Đang chuẩn bị liên kết để tải về tài liệu:
Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triplenegative breast cancer: A systematic review and meta-analysis

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efcacy in advanced triple negative breast cancer (TNBC) patients, but the results are controversial in neoadjuvant chemotherapy (NACT) stage. The purpose of this study is to evaluate the efcacy and safety after NACT plus ICIs in early TNBC patients. |

TÀI LIỆU LIÊN QUAN

Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme

Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma

Re-challenging immune checkpoint inhibitor in a patient with advanced nonsmall cell lung cancer: A case report

The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

Questionnaire-based detection of immunerelated adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

The epigenetic immunomodulator, HBI8000, enhances the response and reverses resistance to checkpoint inhibitors

The role of immune checkpoint inhibitor pembrolizumab in treatment of patients with non small cell lung cancer: Review

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: Causal modeling, timing, and classes of concomitant medications

Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.